- Shares of Immunovant surged over 60% in premarket trading on Tuesday, after the drug developer said its antibody treatment succeeded in an early-stage trial.
Immunovant's experimental drug reduced the levels of IgG, or immunoglobulin antibodies, that cause inflammation and disease. The company is developing its antibody drug, IMVT-1402, as an under-the-skin injection to potentially treat autoimmune diseases. Shares of Roivant Sciences, Immunovant's largest shareholder with a 56.5% stake, according to LSEG data, also rose nearly 13% to $11.51 before the bell.
Based on last close, Immunovant shares have risen 14.3% so far this year, giving it a market capitalization of $2.65 billion, according to LSEG data.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: